The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The composition of the gut microbiome can control innate and adaptive immunity and has emerged as a key regulator of tumor growth, especially in the context of immune checkpoint blockade (ICB) therapy. However, the underlying mechanisms for how the microbiome affects tumor growth remain unclear. Pancreatic ductal adenocarcinoma (PDAC) tends to be refractory to therapy, including ICB. Using a nontargeted, liquid chromatography–tandem mass spectrometry–based metabolomic screen, we identified the gut microbe–derived metabolite trimethylamine N -oxide (TMAO), which enhanced antitumor immunity to PDAC. Delivery of TMAO intraperitoneally or via a dietary choline supplement to orthotopic PDAC-bearing mice reduced tumor growth, associated with an immunostimulatory tumor-associated macrophage (TAM) phenotype, and activated effector T cell response in the tumor microenvironment. Mechanistically, TMAO potentiated the type I interferon (IFN) pathway and conferred antitumor effects in a type I IFN–dependent manner. Delivering TMAO-primed macrophages intravenously produced similar antitumor effects. Combining TMAO with ICB (anti-PD1 and/or anti-Tim3) in a mouse model of PDAC significantly reduced tumor burden and improved survival beyond TMAO or ICB alone. Last, the levels of bacteria containing CutC (an enzyme that generates trimethylamine, the TMAO precursor) correlated with long-term survival in patients with PDAC and improved response to anti-PD1 in patients with melanoma. Together, our study identifies the gut microbial metabolite TMAO as a driver of antitumor immunity and lays the groundwork for potential therapeutic strategies targeting TMAO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [170]
In the citing paper
“However, this effect appears to be context-dependent, as preclinical studies in breast159 and pancreatic cancer models160 indicate that TMAO may improve responses to ICIs (Fig. 3a).”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [160]
In the citing paper
“For instance, TMAO and its microbial precursors reprogrammed tumor-associated macrophages toward a pro-inflammatory, type I interferon (IFN)-dependent phenotype, augmenting CD8+ T-cell activity and potentiating anti-PD-1 efficacy in murine pancreatic cancer.160”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [160]
In the citing paper
“In an orthotopic PDAC mouse model, TMAO rendered tumours responsive to anti-PD-1 and anti-TIM3 antibodies170.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 2×
“M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.”
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302 · cited 2×
“Reads were aligned against a collection of CutC reference protein sequences that was downloaded through NCBI Reference Sequence Database bacterial (RefSeq), using BlastX (60) with E value < 1 × 10−7.”
MethodFast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 1×
“RNA-seq data were aligned using the bowtie2 (49) algorithm against hg19 human or mm10 mouse genome version, and the RSEM v1.”
MethodCytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179 · cited 1×
“12 software (50) was used to estimate read counts and RPKM (reads per kilobase, per million mapped reads) values using gene information from human Ensembl transcriptome version GRCh37.”
MethodIntegrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508 · cited 1×
“Cell clustering, marker identification, and visualization were performed using Seurat v4 (55).”
MethodThe Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cited by
Items 201–300 of 341
Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms
Wu, Y., Jiang, X., Yu, Z., Xing, Z., Ma, Y., & Qing, H. (2024) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928269276231120103256 · Cited by 6
Hu, X., Ma, C., & Kong, X. (2024) · Cancer Screening and Prevention · doi:10.14218/csp.2024.00017 · Cited by 5
Sindaco, M., Mercanti, L., Puca, V., Mazzone, M., Marcantonio, M. C. D., Muraro, R., Fiordaliso, M., & Mincione, G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1519277 · Cited by 5
Trimethylamine-N-oxide: the microbial cue in immune-mediated disorders
Mirji, G., Bhat, S. A., & Shinde, R. S. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.02.008 · Cited by 5
Self-citationThe Role of the Intestinal Microbiome in Multiple Sclerosis—Lessons to Be Learned from Hippocrates
El-Sayed, M. M., Mohak, S., Gala, D., Fabian, R., Péterfi, Z., & Fábián, Z. (2023) · Biology · doi:10.3390/biology12121463 · Cited by 6
“At the species level, Escherichia coli (1.87% of total species) and the Enterococcus faecium (0.04% of total species) of the Enterobacterales and Lactobacillales orders, respectively, are the overrepresented in the lower GI tract [129].”
InfluentialSelf-citationShi, L., Guo, M., Shi, C., Gao, G., Xu, X., Zhang, C., Fu, J., Ni, Y., Wang, F., Xue, X., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05666-w · Cited by 5
“However, recent work strongly supports the idea that TMAO can drive immune activation and promotes anti-tumor immunity (Mirji et al. 2022; Wang et al. 2022).”
BackgroundLocal Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors
Silva-Pilipich, N., Covo-Vergara, Á., & Smerdou, C. (2023) · Cancers · doi:10.3390/cancers15082352 · Cited by 5
Cancer Metabolism Historical Perspectives: A Chronicle of Controversies and Consensus
Dang, C. V. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041530 · Cited by 9
Self-citationImplications of gut microbiota in hepatic and pancreatic diseases: Gut-liver-pancreas axis
Abdelwahab, M. M., Ghattas, A. S., & Tawheed, A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i9.109965 · Cited by 5
Harnessing cuproptosis for pancreatic cancer therapy: From molecular insights to clinical prospects
Darzi, A., Boroumandi, S., Khajegi, P., Dehdashti, M., Abdali, P., Amerinia, M. M., Kheirkhah, F., Ajalli, M. M., & Shokouhfar, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118852 · Cited by 4
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects
Liu, Y., Miao, K., & Yang, X. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.01.001 · Cited by 4
Feng, H., Chen, K., Xi, Z., Xia, B., Chen, X., Huang, Y., Huang, Z., Guo, J., Zhu, D., Ling, F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68649-0 · Cited by 4
Gut microbial metabolites and immune-related diseases
Guo, J., Yin, X., Wang, K., & Jiang, C. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00031-7 · Cited by 6
Yu, L., Peng, S., Chen, X., Wu, T., Dong, L., Luo, J., Xu, S., Zhou, J., Zhao, X., Zheng, L., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.03.019 · Cited by 5
Lin, Z., Mu, S., Zhang, W., Guo, Y., Dong, C., Song, L., Zhang, H., Wu, R., Luo, P., & Liang, L. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102428 · Cited by 4
Gut microbiota in melanoma: Effects and pathogeneses
Liu, W., Yang, X., Zhou, Y., Huang, Z., & Huang, J. H. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128144 · Cited by 5
Microbiome dynamics in immune checkpoint blockade
Kim, C. W., Kim, H.-J., & Lee, H. K. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.013 · Cited by 5
Rimini, M., Montes, M., Amadeo, E., Vitiello, F., Kudo, M., Tada, T., Suda, G., Shimose, S., Lonardi, S., Finkelmeier, F., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-70928-z · Cited by 4
“Another consideration is that metformin has been shown to negatively modulate the immune system by increasing the peripheral proportions of CD4 + and CD8 + regulatory T cells while decreasing CD4 + T helper cell 17 levels 20 .”
BackgroundDonaubauer, A.-J., Frey, B., Weber, M., Allner, M., Vogl, C., Almajali, O., Kuczera, L., Tamse, H., Balk, M., Müller, S. K., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1451035 · Cited by 6
Microbiome in Neuroblastoma: A Virgin Island in the World of Onco-Microbiome
Giri, A. K., Subramanian, P., Periyasamy, L., Aravindan, S., & Aravindan, N. (2025) · Cells · doi:10.3390/cells14151218 · Cited by 3
Wang, Z., Li, X., & Sun, X. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189422 · Cited by 7
The microbiome shaping cancer development, progression, and therapeutic response
Salihoğlu, R. (2025) · Physiological Genomics · doi:10.1152/physiolgenomics.00091.2025 · Cited by 3
Unveiling the gut-pancreas axis: microbial influence on stemness and tumor microenvironment of PDAC
Arikath, K., Batra, S. K., & Ponnusamy, M. P. (2025) · Stem Cells · doi:10.1093/stmcls/sxaf064 · Cited by 4
Sun, J., Sun, T., Zhang, Y., Liu, B., & Yin, L. (2026) · Communications Biology · doi:10.1038/s42003-026-09593-z · Cited by 5
“To deplete macrophages in mice, clodronate liposomes (100 μ L per injection, 40337ES10, Yeasen, Shanghai, China) were administered to the peritoneum of mice starting 3 days before single-cell suspension injection, which was repeated every 4 days until the endpoint of the experiment.”
The Role and Mechanism of Gut Microbiota and Metabolites in Vascular Calcification
Cao, X., Zhang, A.-Y., Li, K.-F., Bie, Y.-W., Xu, G.-W., Zhou, C.-Y., Ma, X., Zhuang, Y., Sun, H.-J., & Zhu, X.-X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031364 · Cited by 3
“Studies have shown that administration of metronidazole, which alters gut microbiota composition, leads to a marked reduction in serum TMAO levels [112], suggesting a strong association between TMAO production and microbial activity.”
Targeting the gut-pancreatic axis: microbial modulation of immunotherapy in pancreatic cancer
Yuan, Y., Zhang, W., & Wang, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1682390 · Cited by 4
The microbiome: regulating anti-tumor immunity
Tao, Y.-L., Wu, X.-X., Wang, J.-R., Liu, M., Liu, Y.-N., Lian, Y.-Q., Liang, Z., & Zhu, S.-F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1781872 · Cited by 5
Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies
Zhang, H., Du, Z., Lu, P., Jiang, A., Guo, Y., Liu, Y., Song, Z., Dai, B., & Zhang, W. (2026) · MedComm · doi:10.1002/mco2.70754 · Cited by 6
“In keeping with these findings, in models of PDAC, the gut-derived metabolite trimethylamine N-oxide (TMAO), when coadministered with anti-PD-1 and/or anti-Tim3 therapy, resulted in a reduction in tumor burden and improved survival over single-agent treatment [ 162 ].”
Metabolites derived from gut microbiota mitigate chemoresistance in pancreatic cancer
Deng, J., Deng, D., Wang, B., Donati, V. L., Frampton, A. E., & Giovannetti, E. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2412045 · Cited by 4
“Mechanistically, this study also found that TMAO enhanced type-I interferon pathway, resulting in an anti-tumor effect [38].”
Isolation of Bacteria and Fungi from Human Pancreatic Tumors and Duodenum
Awad, D., Attebury, H., Hong, R., Kim, K., Zhang, L., Bischoff, A., Achi, S. C., denDekker, A., Lesniak, N., The, S., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2695522 · Cited by 3
“19-21 Furthermore, the bacterial species isolated from our PDAC tumor and duodenal tissues have been shown to induce metabolic changes that drive pathogenicity in pancreatic cancer cells.”
Investigating the Influence of Gut Microbiota-related Metabolites in Gastrointestinal Cancer
Marzhoseyni, Z., Shaghaghi, Z., Alvandi, M., & Shirvani, M. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096274860231111210214 · Cited by 4
Zabolotneva, A. A., Shatova, O. P., Shegai, P. V., & Shestopalov, A. V. (2023) · Oncology Advances · doi:10.14218/ona.2023.00014 · Cited by 3
Zhang, G., Huang, X., Li, R., Hong, S., Zheng, X., Huang, K., Wang, J., Tao, Q., & Shi, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139078 · Cited by 4
RetractedXiang, S., Shan, Y., Shi-hong, X., Wang, J., Luo, M., Zhou, J., & Chen, Q. (2025) · Advanced Science · doi:10.1002/advs.202501820 · Cited by 2
Pinnelli, V. B., Jayashankar, C. A., Kandi, V., Spandana, P., Manish, G. R., Hussain, M. H., Akshay, A. S., Kavitha, R., Jp, R., Surendra Babu, T., et al. (2025) · Cureus · doi:10.7759/cureus.94362 · Cited by 3
“A recent study found that the breakdown of bile acid metabolites and tryptophan generated from diet aided by GM promotes brain cell development and function while preventing inflammation of the central nervous system (CNS) [19].”
Invisible influencers: the tumor microbiome’s impact on immunotherapy in colorectal cancer (CRC)
Omar, T. M., Al-Hussainy, A. F., Jyothi, S. R., Nayak, P. P., Janney, J. B., Singh, G., Polatova, D., Sameer, H. N., Salih, R. M., Adil, M., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2579656 · Cited by 3
“Elevated CutC-expressing bacteria, which produce TMAO, correlate with better responses to anti-PD1 therapy and longer survival, high-lighting TMAO as a promising therapeutic target [92].”
Fukuba, N., Moriyama, I., Onoe, M., Kodama, Y., Kotani, S., Oka, A., Oshima, N., Kawashima, K., Ishimura, N., & Ishihara, S. (2025) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00202-3 · Cited by 2
“Kim reported that TMAO, a gut microbiota-derived metabolite, reduces immunosuppression and enhances the efficacy of immune checkpoint inhibitors, indicating the potential for gut-targeted intervention agents to improve treatment outcomes [28].”
Shaping the Tumor Microenvironment: Insights from Host–Microbiota Interactions
Lam, K. C., & Goldszmid, R. S. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1350 · Cited by 2
Tumor-associated bacterial effectors: novel frontiers in tumor biology and immunity
Dai, J.-H., Lu, Y.-Q., Feng, S.-Y., Tan, X.-R., Li, L., Zeng, Y.-C., Chen, J., Ma, J., & Liu, N. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.04.034 · Cited by 4
Samanthapudi, V. S. K., Mendoza, K. C. O., Puvvala, S. P., Kamma, S., & Kotla, S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104703 · Cited by 2
Eysha, M., Fouani, M., Munir, M., Black, M., Long, A., Elchouemi, M., Singh, S., & Abid, M. B. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1787954 · Cited by 2
The relationship between gut microbiota and cancer immune response and immunotherapy
Jia, Y., Liu, Y., & Liu, J. Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1833138 · Cited by 2
Wang, Y., Zhao, L., Zou, Y., & Nie, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1775938 · Cited by 2
Xu, R., Liu, S., Li, L., Zhang, Y., Fang, B.-Q., Luo, G., & Wang, X. (2024) · International Journal of Impotence Research · doi:10.1038/s41443-024-00824-7 · Cited by 2
“This study demonstrated a possible causal relationship between gut microbiota and ED risk through MR analysis, providing new potential possibilities for the prevention and treatment of ED.”
Beyond the tumor: the gut microbiome as a key player in immunotherapy efficacy and resistance
Zhao, Y., Liu, W., & Hu, Y. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04315-4 · Cited by 3
“Other metabolites such as trimethylamine N-oxide (TMAO) have been shown to stimulate innate immunity and increase T cell tumor infiltration, particularly in pancreatic cancer models (Mirji et al. 2022).”
Liu, Q., Yu, L., Zhang, Z., Zhuang, Z., Tian, W., Wang, A., & Xu, H. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05038-y · Cited by 2
“Current research has confirmed that human-microbial co-metabolism is closely associated to the development of various diseases [44, 45] Together, gut bacteria modulate host metabolic processes and continually shape the immune system [46].”
Self-citationTargeting the Senescent Tumor Microenvironment to Sensitize Immunotherapy
Sun, W. C. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/te6m0d54 · Cited by 1
“Notably, gut microbiota - derived trimethylamine N - oxide (TMAO) enhances type I interferon signaling in pancreatic ductal adenocarcinoma [6], suggesting that microbial modulation could serve as an immunotherapeutic adjuvant.”
Chen, Z., Guan, D., Wang, Y., & Gou, Y. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.06.004 · Cited by 1
Lei, O.-K., Yang, J., Kang, H., & Li, Z. (2025) · Nutrients · doi:10.3390/nu17132137 · Cited by 3
Hu, L., Zhu, Y., Wu, C., Liu, X., Wang, Q., Huang, Y., Liu, H., Chen, X., Wu, W., & Jiang, H. (2025) · Smart Medicine · doi:10.1002/smmd.70015 · Cited by 1
“It has been used in cancer and infectious disease research [25–27], indicating its potential for studying CSOM with or without cholesteatoma.”
The role of Gram‐positive cocci in cancer initiation, progression, and its application in therapy
Liang, C., Zhou, Z., Li, P., & Xiao, H. (2025) · International Journal of Cancer · doi:10.1002/ijc.70063 · Cited by 1
The Role of the Microbiome in Pancreas Cancer
Awad, D., & Daley, D. (2025) · Surgical Clinics of North America · doi:10.1016/j.suc.2025.06.001 · Cited by 2
Microbiota in pancreatic ductal adenocarcinoma progression and therapy: The hidden players
Hu, X., Kong, F., Chen, J., Li, Z., Cai, Z., & Kong, X. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003986 · Cited by 1
“…tumor growth without obvious side effects [111] Dietary choline supplementation/TMAO supplementation Orthotopic PDAC mice Reduced tumor growth [112] Dietary tryptophan modulation/3-IAA supplementation Subcutaneous PDAC mice; orthotopic PDAC mice Enhanced chemosensitivity [87] FMT (donors:…”
Gut microbiome‐derived metabolites show promise in cancer research and therapy
Yang, K., Wang, Y., Tang, D., Li, P., & Du, L. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70096 · Cited by 1
Microbiome‐urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation
Xu, H., Li, Z., Yang, L., Zheng, J., Li, W., Liao, R., Huang, W., Sun, B., Li, Z., Ma, C., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70081 · Cited by 1
“It has been shown to activate CD8 + T cells and promote antitumor immunity in breast and pancreatic cancer models [151, 152].”
Zheng, L., Huang, J., Ni, H., Kuang, X., Liao, J., Qu, Z., Liu, H., Huang, C., Yu, L., Dai, L., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.03.013 · Cited by 1
Drespling, J., Heelemann, S., Strathmeyer, S., Kühn, H., Schwarz, B., & Mundhenk, L. (2026) · PLoS ONE · doi:10.1371/journal.pone.0346250 · Cited by 1
“Certain molecules which had been reported to modulate immune cell function such as creatinine, creatine and TMAO [53–55] were also detected here.”
Microbiota as a modulator of drug response: targeting microbial–drug crosstalk in cancer therapy
Zhao, T., Liu, M., Qiu, L. X., Zhang, H., Zhang, N., Liu, Z., Xia, Z., Luo, P., Huang, J., & Cheng, Q. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2651930 · Cited by 1
The role of gut microbiota in obesity-related cancers
Shi, W., Song, B., Xia, S., & Jia, D. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.04.002 · Cited by 1
MANFOUO, W. Q. W., & 华晔 (2026) · Discover Oncology · doi:10.1007/s12672-026-05030-z · Cited by 1
Cai, Y., Jin, J., Wang, Y., Han, D., Yu, X., Jin, F., Li, M. D., Li, Y., & Li, X. (2026) · BMC Medicine · doi:10.1186/s12916-026-04898-6 · Cited by 2
“Current research also suggests that TMAO may enhance T cell activity through the IFN signaling pathway, although the precise mechanism remains unclear [86] (Fig.”
Microbiome: a driver of pancreatic inflammation and tumorigenesis
Alam, A., Mayengbam, S. S., Senchanthisai, S., Bektas, E. I., & Dey, P. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.04.006 · Cited by 1
Gut microbial metabolites for potentiating cancer therapy
Kamrad, S., Gagliani, N., Lawley, T. D., Patil, K. R., & Tintelnot, J. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.04.005 · Cited by 2
The dialogue between breast cancer and microorganisms
Zeng, Y., Jiang, Y., Huang, Y., Yin, S., Yang, Z., & Zhang, F. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1738739 · Cited by 1
“CD8+ T cells play a pivotal role in HER2/neu+ breast cancer pathogenesis, with TMAO produced by Clostridium species serving to potentiate this immunomodulatory effect (Mirji et al., 2022; Wang et al., 2022; Lu et al., 2024).”
Tumor Microbial Burden Drives Immune Responses through Regulation of Interferon Signaling
Liu, H., Jang, J., Peng, F., Rajaei, H., Chandra, V., Li, L., Rupani, D. N., Taghinezhad‐S, S., Zhao, Y., Faraoni, E. Y., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1908 · Cited by 1
Gut metabolites: key factors in the cross-talk between the gut microbiota and tumor immunotherapy
Zeng, L., Ren, Y., Huang, H., Wang, Q., Li, H., Song, J., He, F., & Li, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1882542 · Cited by 1
Chen, Y., Nian, F., Wu, S., Yuan, T., Ma, Y., Cao, J., Zhang, Y., Liu, W., Tang, W., Zhang, D., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01222-2 · Cited by 3
“The lysates were used for subsequent [ 13 C]UDP-galactose analyses.”
InfluentialLi, T.-T., Chen, X., Wang, F., Tang, Y. A., Sim, M., Xiao, L., Jin, W., Shi, H., Ma, J. Y., Yang, X., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03269-z · Cited by 1
Pei, X., Zhao, J., Luo, R. K., Da, L., Li, E., Zhu, H., Li, Y., Luo, Y., Tian, K., Wang, Z., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1407312 · Cited by 1
Ho, M. P., & Bonavida, B. (2025) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2025058633 · Cited by 1
Stieg, D. C., Parris, J. L. D., Yang, T. H. L., Mirji, G., Reiser, S. K., Murali, N., Werts, M., Barnoud, T., Lu, D. Y., Shinde, R. S., et al. (2023) · doi:10.1158/2767-9764.c.6702845
Self-citationProgress in understanding of relationship between intestinal microecology and pancreatic cancer
Qin, Y.-M., & Sha, J. (2023) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v31.i24.1001
The Emerging Role of the Microbiome in Carcinogenesis
Gates, T. J., Dietz, M. A., Martell, M., Balbo, S., Subramanian, S., & Staley, C. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00093-0
Understanding the resistome of the human microbiome: A metagenomic approach
Barik, S., Kannoth, S., Deepthi, M., José, M., Prabhu, D. C., Sadanandan, S., & Grace, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91631-8.00016-0 · Cited by 1
Ni, Q., Zhang, H., Wang, Z., So, W. Y., Wang, C., Chen, S., & Liao, Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5089240
The Role of TMAO in the Development of HCC by Activating the NLRP3 Inflammasome
许, 凤. (2025) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2025.152046
Righetti, F., Massara, M., & Calcinotto, A. (2025) · The microbiomes of humans, animals, plants, and the environment · doi:10.1007/978-3-031-84065-4_8
Prospect of interdisciplinary research on gut microbiota and colorectal cancer immunotherapy
Lu, Y., Zhang, Z., Chen, L., Xue, P., Zhang, Y., Li, Y., & Guo, H. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104832 · Cited by 1
Zhou, X., Zhou, Y., Xu, Y., Wang, Z., & Lv, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-03161-3
“TMAO has been shown to directly induce pro-inflammatory mediators like NLRP3 and mitochondrial ROS while suppressing anti-inflammatory factors like IL-10, thus driving inflammation [65, 66].”
Guan, S., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610111
Guan, S.-W., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610075
Guan, S., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610105
Guan, S., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610126
Wang, C.-Y., Kuang, X., Wang, Q.-Q., Zhang, G.-Q., Cheng, Z., Deng, Z.-X., & Guo, F.-B. (2023) · Figshare · doi:10.6084/m9.figshare.24031020
Guan, S., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610120
Guan, S., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610069
Guan, S., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610093
Guan, S.-W., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610108
Guan, S.-W., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610114
Guan, S.-W., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610072
Guan, S., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610123
Guan, S., Lin, Q., Wu, X.-D., & Yu, H.-B. (2024) · Figshare · doi:10.6084/m9.figshare.26610117
Jin, Q., Liu, Y., Tong, Q., Tang, B., Liang, F., & Zeng, L. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1666682
Zheng, G., Zhang, W., Jiang, T., Chen, Y., Cheng, Y., Shi, J., Ji, J., Zhao, L., Zhao, Z., Liu, S., et al. (2026) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000186
The cancer–microbiome axis: Mechanisms and emerging therapeutic strategies
Walker, M., Schwarzfischer, M., & Scharl, M. M. (2026) · Seminars in Immunopathology · doi:10.1007/s00281-026-01072-1
Baltacioglu, A., Acar, O., Sonmez, C., Sağlıcan, Y., Argun, Ö. B., Kural, A. R., Yıldırım, A., İnce, Ü., Serdar, M. A., & Özpınar, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083591
“Dysbiosis and increased microbial trimethy-lamine production lead to higher systemic TMAO levels, which in turn exacerbate chronic inflammation and oxidative stress [33,34].”
Zhang, Z., Gao, Y., Yuan, F., Wang, Q., Zhang, W., & Liu, R. (2026) · Health and Metabolism · doi:10.53941/hm.2026.100010 · Cited by 1
Min, K., Kim, S. I., Lee, M., Kim, Y., Jeong, C., Kim, S., Kim, S. J., Kim, H., Cho, B., Joo, Y., et al. (2026) · Microbiome · doi:10.1186/s40168-026-02373-1 · Cited by 1
“B Summary of findings from the study by Mirji et al., 2022 [50].”
Pancreatic Cancer in the Holobiont and Therapeutic Targets: A Review
Terry, C., Hall, L. A., Halle-Smith, J. M., Edwards, L. A., Sivakumar, S., Chapple, I., Beggs, A. D., Iqbal, T. H., & Roberts, K. J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093225
“Microbial modulation has also been linked to altered PD-1 pathway activity, relevant to immune checkpoint responsiveness in pancreatic cancer [16,36,87].”
Metadata
- Authors
- Mirji, G., Worth, A., Bhat, S. A., El Sayed, M., Kannan, T., Goldman, A. R., Tang, H.-Y., Liu, Q., Auslander, N., Dang, C. V., Abdel-Mohsen, M., Kossenkov, A., Stanger, B. Z., & Shinde, R. S.
- Affiliations
- The Wistar Institute (US)
- Immunology, Microenvironment and Metastasis Program, the Wistar Institute, Philadelphia, PA, USA.
- University of Pennsylvania (US)
- Corresponding author
- Shinde, Rahul S.
- ORCID
- Venue
- Science Immunology
- Published
- 2022-09-30
- Volume
- 7
- Issue
- 75
- Pages
- eabn0704-eabn0704
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC9925043
- OpenAlex
- W4295519447
- Cited by
- 327
- References
- 62
- Citations by year
- 2026: 83 · 2025: 91 · 2024: 89 · 2023: 62 · 2022: 2
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (1s10od023586-01)
- National Cancer Institute (R01CA057341, R21CA259240, R50CA221838, R50CA211199, R01CA252225, P30CA010815)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- trimethylamine N-oxide, gut microbiota, pancreatic ductal adenocarcinoma, immune checkpoint blockade, antitumor immunity, tumor-associated macrophages, type I interferon pathway, choline, CutC, anti-PD-1, effector T cells, tumor microenvironment, melanoma
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Methylamines, Pancreatic Neoplasms, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.